Table 2. Comparison of chemotherapy versus chemotherapy plus rituximab in RCTs.
| OR | PFS | OS | ||||
| CVP R-CVP Marcus 2008 (21) |
64 % 81 % |
(p < 0.0001) | 18 mo 48 mo |
(p < 0.001) | 77 % 83 % |
(p = 0.029) |
| CHOP R-CHOP Hiddemann 2005 (19) |
90 % 96 % |
(p = 0.011) | 31 mo n. r. |
(p = 0.0006) | 90 % 95 % |
(p = 0.016) |
| MCP R-MCP Herold 2007 (20) |
75 % 92 % |
(p = 0.0009) | 29 mo n. r. |
(p < 0.0001) | 74 % 87 % |
(p = 0.0096) |
| CHVP+IFN R-CHVP+IFN Salles 2008 (22) |
72 % 81 % |
(p < 0.0001) | 35 mo n. r. |
(p < 0.0001) | 79 % 84 % |
(p = 0.029) |
CHOP, cyclosphosphamide, hydroxydaunorubicin, vincristine, prednisone;
CHVP, cyclophosphamide, hydroxydaunorubicin, VP 16, prednisone;
CVP, cyclophosphamide, vincristine, prednisone; IFN, interferon alpha;
MCP, mitoxantrone, cyclophosphamide, prednisone; mo, months; n. r., not reached;
OR, overall response; OS, overall survival; PFS, progression-free survival
R; rituximab; RCT, randomized controlled trial